At a glance
- Originator Dendreon San Diego LLC
- Developer Dendreon San Diego LLC; Schering-Plough
- Class Anticoagulants; Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary thrombosis; Unstable angina pectoris; Venous thrombosis
Most Recent Events
- 25 Aug 1998 Discontinued-I for Coronary thrombosis in United Kingdom (Unknown route)
- 25 Aug 1998 Discontinued-I for Coronary thrombosis in USA (Unknown route)
- 25 Aug 1998 Discontinued-I for Unstable angina pectoris in United Kingdom (Unknown route)